
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
April 10, 2025
Host Carmel Fisher interviews CEO Chris Bunka on Lexaria’s advancement in creating a superior absorption system for fat soluble nutrients.